Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Riess

Showing results (1321-1330 of 1,489) with videos related to

Pageof 149
Sort By:
JTO Clinical and Research Reports|March 7, 2023
Osimertinib in NSCLC With Atypical <i>EGFR</i>-Activating Mutations: A Retrospective Multicenter StudyJingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, et al.
Communications Biology|May 11, 2023
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinibIsmail M Meraz, Mourad Majidi, Bingliang Fang, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|November 22, 2024
General anaesthesia and deep sedation for monopolar pulsed field ablation using a lattice-tip catheter combined with a novel three-dimensional mapping systemAndreas Rillig, Jun Hirokami, Fabian Moser, et al.
Clinical Lung Cancer|November 27, 2025
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trialJames Chih-Hsin Yang, Yuh-Min Chen, Ullas Batra, et al.
Lung Cancer (Amsterdam, Netherlands)|June 26, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARDIsamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, et al.
Clinical Lung Cancer|February 28, 2019
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study ProtocolBenjamin Levy, Luis Paz-Ares, Jaafar Bennouna, et al.
The Lancet. HIV|April 12, 2025
Impact of quasi-elimination of Wuchereria bancrofti on HIV incidence in southwest Tanzania: a 12-year prospective cohort studyInge Kroidl, Thomas F Marandu, Lucas Maganga, et al.
Clinical Lung Cancer|August 14, 2021
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)Helena A Yu, Sarah B Goldberg, Xiuning Le, et al.
The Journal of Clinical Investigation|May 8, 2019
Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's diseaseElena Vezzoli, Ilaria Caron, Francesca Talpo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2018
Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLCJonathan W Riess, David R Gandara, Garrett M Frampton, et al.
Pageof 149

Showing results (1321-1330 of 1,489) with videos related to

Sort By:
Pageof 149
JTO Clinical and Research Reports|March 7, 2023
Osimertinib in NSCLC With Atypical <i>EGFR</i>-Activating Mutations: A Retrospective Multicenter StudyJingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, et al.
Communications Biology|May 11, 2023
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinibIsmail M Meraz, Mourad Majidi, Bingliang Fang, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|November 22, 2024
General anaesthesia and deep sedation for monopolar pulsed field ablation using a lattice-tip catheter combined with a novel three-dimensional mapping systemAndreas Rillig, Jun Hirokami, Fabian Moser, et al.
Clinical Lung Cancer|November 27, 2025
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trialJames Chih-Hsin Yang, Yuh-Min Chen, Ullas Batra, et al.
Lung Cancer (Amsterdam, Netherlands)|June 26, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARDIsamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, et al.
Clinical Lung Cancer|February 28, 2019
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study ProtocolBenjamin Levy, Luis Paz-Ares, Jaafar Bennouna, et al.
The Lancet. HIV|April 12, 2025
Impact of quasi-elimination of Wuchereria bancrofti on HIV incidence in southwest Tanzania: a 12-year prospective cohort studyInge Kroidl, Thomas F Marandu, Lucas Maganga, et al.
Clinical Lung Cancer|August 14, 2021
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)Helena A Yu, Sarah B Goldberg, Xiuning Le, et al.
The Journal of Clinical Investigation|May 8, 2019
Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's diseaseElena Vezzoli, Ilaria Caron, Francesca Talpo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2018
Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLCJonathan W Riess, David R Gandara, Garrett M Frampton, et al.
Pageof 149